ALBANY MEDICAL COLLEGE
A novel c-di-AMP-based recombinant BCG vaccine
A novel c-di-AMP-based recombinant BCG vaccine is a funding opportunity from ALBANY MEDICAL COLLEGE, up to 203750, closing January 31, 2027.
Jan 31, 2027
(184d left)Overview
SUMMARY Tuberculosis (TB) remains a global epidemic, with one-fourth of the current world population infected and approximately 10 million new active cases annually. However, our knowledge about the causative agent, Mycobacterium tuberculosis (Mtb), is still limited, and the only licensed TB vaccine (BCG) is…